🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug

Published 09/30/2024, 01:49 PM
Updated 09/30/2024, 04:00 PM
© Reuters. FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo
BMY
-

(Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene (NASDAQ:CELG) shareholders by delaying federal approval for the cancer drug Breyanzi and two other drugs developed by Celgene.

U.S. District Judge Jesse Furman in Manhattan said UMB Bank was never properly appointed trustee for shareholders owning "contingent value rights" (CVR) because its hiring was supported by a majority of beneficial owners, not registered owners.

Furman said that "inexplicable failure" doomed the lawsuit that UMB filed on CVR holders' behalf in June 2021, a few months after purportedly replacing a different trustee, and 17 months after Bristol Myers bought Celgene for $80.3 billion.

"After three years of litigation and with so much money at stake, the court does not reach that conclusion lightly," Furman wrote. "UMB has no one to blame for that result but itself." He said a "properly appointed" trustee can refile the case.

Neither lawyers for UMB nor the Kansas City, Missouri-based bank immediately responded to requests for comment. Bristol Myers and its lawyers did not immediately respond to similar requests.

The merger called for Bristol Myers to pay CVR holders an extra $9 per share in cash if it won U.S. Food and Drug Administration approval of Liso-Cel, which is sold as Breyanzi, and Ozanimod by Dec. 31, 2020, and Ide-cel by March 31, 2021.

CVR holders accused Bristol Myers of being slow to submit critical information to the FDA and to ready plants for inspection, hoping to delay approvals and avoid the $6.4 billion payout.

Bristol Myers won FDA approval for Breyanzi on Feb. 5, 2021, to treat non-Hodgkin's lymphoma.

CVR holders are appealing Furman's February dismissal of a separate lawsuit they filed directly, accusing Bristol Myers of securities fraud.

© Reuters. FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo

Also in 2024, state court judges in New York and New Jersey dismissed lawsuits by CVR holders who said Bristol Myers' registration statement for the Celgene merger failed to disclose it had no intention to obtain FDA approval for Breyanzi in time.

The case is UMB Bank NA v Bristol-Myers Squibb (NYSE:BMY) Co, U.S. District Court, Southern District of New York, No. 21-04897.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.